About Concordia International Corp.
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CXRX
- Previous Close: $2.50
- 50 Day Moving Average: $2.31
- 200 Day Moving Average: $4.70
- 52-Week Range: $1.69 - $35.23
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 0.94
- P/E Growth: 0.00
- Market Cap: $127.54M
- Outstanding Shares: 51,017,000
- Beta: 0.12
- Net Margins: -81.40%
- Return on Equity: 22.81%
- Return on Assets: 3.48%
Companies Related to Concordia International Corp.:
- Debt-to-Equity Ratio: 10.65%
- Current Ratio: 1.02%
- Quick Ratio: 0.82%
What is Concordia International Corp.'s stock symbol?
Concordia International Corp. trades on the NASDAQ under the ticker symbol "CXRX."
How often does Concordia International Corp. pay dividends? What is the dividend yield for Concordia International Corp.?
Concordia International Corp. declared a quarterly dividend on Monday, May 16th. Shareholders of record on Friday, July 15th will be paid a dividend of $0.075 per share on Friday, July 29th. This represents a $0.30 dividend on an annualized basis and a dividend yield of 12.00%. The ex-dividend date is Wednesday, July 13th.
Where is Concordia International Corp.'s stock going? Where will Concordia International Corp.'s stock price be in 2017?
11 brokers have issued 12 month price objectives for Concordia International Corp.'s stock. Their forecasts range from $0.50 to $73.00. On average, they anticipate Concordia International Corp.'s stock price to reach $28.68 in the next year.
What are analysts saying about Concordia International Corp. stock?
Here are some recent quotes from research analysts about Concordia International Corp. stock:
According to Zacks Investment Research, "Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada. " (1/10/2017)
Goldman Sachs Group, Inc. (The) analysts commented, "multiple challenges, including levered balance sheets, intensifying pricing pressure and deteriorating fundamentals." The brokerage's top picks are Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) and Horizon Pharma PLC (NASDAQ: HZNP)."Our analysis reveals that much of the M&A has destroyed value, and balance sheets are now bloated — making traditional multiples insufficient to capture the full story," analyst Stephan Stewart wrote in a note.Stewart expects "limited M&A, increasing payer pressure and ongoing government focus to limit branded price aggression" and "sees branded companies with durable growth and pipelines with near-term commercial opportunities as best positioned."Related Link: Biocept Is An Emerging Leader In Liquid Biopsy; Roth Starts At BuyMeanwhile, the analyst said the generics sector faces "increased manufacturer competition, FDA's focus on reducing its backlog, and purchaser consolidation" amid continued pricing pressures. "In this context, scale, portfolio exposures and pipelines increasingly matter and we await signs of stabilization before getting more positive," Stewart highlighted.Specialty Pharma Picks And Panshttp://www.benzinga.com/analyst-ratings/analyst-color/16/06/8073266/goldman-sees-26-upside-in-jazz-pharma-shares">Stewart likes Buy-rated Jazz Pharma, as it "boasts leading organic growth, returns and balance sheet quality, with 2016 catalysts to drive shares higher."In addition, the analyst also hailed Buy-rated Horizon Pharma's emerging orphan portfolio.On the flipside, the analyst recommends investors sell Impax Laboratories Inc (NASDAQ: IPXL), as he sees "high expectations, premium valuation, increasing competition and tail risk limiting relative upside."Stewart said he would avoid companies with "sizeable exposure to the generic pain market," such as Endo International plc - Ordinary Shares (NASDAQ: ENDP) and Mallinckrodt PLC (NYSE: MNK) — both Neutral rated.Related Link: Goldman Likes Horizon Pharma's Emerging Orphan FranchiseThe analyst noted he is concerned by the durability of Neutral-rated Concordia Healthcare Corp (NASDAQ: CXRX)'s North American portfolio, on historical price reliance. "However, the company's ongoing strategic review could limit downside."The analyst also likes Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s (Neutral) "biosimilar and novel pipeline opportunities, but expect(s) litigation around its near-term generic Copaxone 40mg opportunity to drive near-term stock performance."Sector CatalystsAmong the sector catalysts, Stewart lists out the following key upcoming events:1. "Expected 1Q17 approval and trial decision on MNTA's generic Copaxone 40mg, which could more than double its current revenue base and provide a path to the more attractive longer term biosimilars and novel compound pipeline.2. "HZNP's 4Q16 phase 3 data for Actimmune in FA, which we believe could be a $500+ million opportunity if approved, versus HZNP's current revenue run rate of ~$1,000 million.3. "JAZZ's anticipated 4Q Phase 3 data for JZP-110, a wake promoting agent with a potentially large addressable market and comfortable $300+ million revenue opportunity versus JAZZ's current revenue base of $1.5 billion." (6/6/2016)
Who owns Concordia International Corp. stock?
Concordia International Corp.'s stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Warlander Asset Management LP (2.75%), Raging Capital Management LLC (0.79%), Public Sector Pension Investment Board (0.69%), Renaissance Technologies LLC (0.56%), Continental Advisors LLC (0.31%) and GLG Partners LP (0.25%).
Who sold Concordia International Corp. stock? Who is selling Concordia International Corp. stock?
Concordia International Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and GLG Partners LP.
Who bought Concordia International Corp. stock? Who is buying Concordia International Corp. stock?
Concordia International Corp.'s stock was acquired by a variety of institutional investors in the last quarter, including Warlander Asset Management LP, Continental Advisors LLC, Partners Group Holding AG and Allianz Asset Management AG.
How do I buy Concordia International Corp. stock?
Shares of Concordia International Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Concordia International Corp. stock cost?
One share of Concordia International Corp. stock can currently be purchased for approximately $2.50.